Skip to main content
Yabao Pharmaceutical Group Co.,Ltd logo

Yabao Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 600351 ISIN · CNE000001CM5 LEI · 65560071PKRS4UHMVU53 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,361 across all filing types
Latest filing 2024-01-02 Transaction in Own Shar…
Country CN China
Listing Shanghai Stock Exchange 600351

About Yabao Pharmaceutical Group Co.,Ltd

http://www.yabao.com.cn

Yabao Pharmaceutical Group Co.,Ltd. focuses on the research, development, manufacturing, and commercialization of pharmaceutical products. The company maintains a specialized portfolio across therapeutic areas including pediatrics, cardiovascular health, and endocrinology. Key offerings include traditional Chinese medicines, chemical drugs, and innovative transdermal patches, such as the Dinggui Erqi Patch. The organization operates integrated production bases and research facilities dedicated to advancing drug delivery systems and biotechnological applications. Its business model emphasizes the modernization of traditional therapies alongside the development of conventional pharmaceuticals to address diverse clinical needs.

Recent filings

Filing Released Lang Actions
亚宝药业集团股份有限公司关于以集中竞价交易方式回购股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from a company about the progress of its share repurchase program, including details on the number of shares repurchased, prices, and total amount spent. It references the company's board approval and regulatory compliance but does not contain financial statements or detailed financial analysis. The content fits the description of a report on the company's transactions in its own shares (share buybacks). Therefore, the appropriate classification is 'Transaction in Own Shares' (POS). The document length and content confirm it is not a full financial report or an announcement of a report publication.
2024-01-02 Chinese
亚宝药业集团股份有限公司关于研发项目暂停临床试验并计提减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by the company about the suspension of a clinical trial for a drug development project and the full impairment of the capitalized R&D costs related to that project. It details the background of the drug, reasons for suspension, accounting treatment of impairment, and the financial impact on the company's profit. The document is relatively short (2207 characters) and focuses on a specific event related to asset impairment and R&D project status. It does not contain comprehensive financial statements or a full financial report. It is not an earnings release or annual/interim report but rather a regulatory announcement about a significant accounting and operational event. Therefore, it fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other categories.
2024-01-02 Chinese
亚宝药业集团股份有限公司关于参与投资杭州华方丰柏投资管理合伙企业（有限合伙）新增有限合伙人及增资的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's participation in an investment partnership, specifically about the addition of a new limited partner and an increase in the partnership's capital. It details changes in the partnership agreement, the new partner's information, and the impact on the company. There are no financial statements, quarterly or annual results, or audit information presented. The document is a formal disclosure of a capital investment update related to the company's financing activities. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 3640 characters, which is consistent with an announcement rather than a full report.
2023-12-28 Chinese
亚宝药业集团股份有限公司关于回购股份比例达到1%暨回购进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from a company about the progress of its share repurchase program, including details on the percentage of shares repurchased, prices, and total amount spent. It references regulatory rules on share buybacks and provides updates on the repurchase progress. The document is short (1041 characters) and focuses on the share repurchase activity rather than financial results or other report types. This fits the definition of a Transaction in Own Shares (POS) filing, which covers company buyback or sale of its own shares.
2023-12-19 Chinese
亚宝药业集团股份有限公司关于取得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a company about obtaining drug registration certificates from a national regulatory authority. It details the approval of pharmaceutical products, their specifications, and regulatory compliance. The document is short (1167 characters) and serves as an official announcement rather than a detailed report or financial filing. It does not contain financial statements, management discussion, or other report content. It is not related to annual reports, earnings, or governance changes. Therefore, it fits best as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2023-12-01 Chinese
亚宝药业集团股份有限公司关于以集中竞价交易方式回购股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the progress of a share repurchase program by the company 亚宝药业集团股份有限公司. It details the number of shares repurchased, the price range, total amount spent, and compliance with relevant regulations. The document does not contain financial statements or detailed financial analysis but focuses on the update of the share buyback activity. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buyback or sale of its own shares.
2023-12-01 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.